



ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

September 24, 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--Sep. 24, 2018-- ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at the Lotte New York Palace in New York City.

The live webcast of the presentation will be available via the "Investors & Media" section of ArQule's website, www.argule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule's pipeline includes: ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in Phase 1 for patients with B-cell malignancies refractory to other therapeutic options; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a Phase 1/2 company-sponsored study for Overgrowth Diseases, in a Phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), and in Phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor, in Phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; and ARQ 761, a β -lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180924005268/en/>

Source: ArQule, Inc.

Corporate Contact:

ArQule, Inc.
Marc Schegerin, M.D.
Senior Vice President
Strategy, Communication and Finance
ir@argule.com
www.ArQule.com

or

Media Contact:

LifeSci Public Relations
Allison Blum, Ph.D., 646-627-8383
Allison@lifescipublicrelations.com